CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Viracta Therapeutics, Inc. - VIRX CFD

0.69
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Viracta Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.69
Open* 0.67
1-Year Change* -65.1%
Day's Range* 0.67 - 0.7
52 wk Range 0.43-2.38
Average Volume (10 days) 99.99K
Average Volume (3 months) 3.56M
Market Cap 19.31M
P/E Ratio -100.00K
Shares Outstanding 38.62M
Revenue N/A
EPS -1.24
Dividend (Yield %) N/A
Beta 0.87
Next Earnings Date Mar 11, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 0.69 0.02 2.99% 0.67 0.70 0.67
Feb 21, 2024 0.69 -0.01 -1.43% 0.70 0.72 0.64
Feb 20, 2024 0.69 0.03 4.55% 0.66 0.70 0.66
Feb 16, 2024 0.66 0.02 3.13% 0.64 0.71 0.64
Feb 15, 2024 0.60 0.00 0.00% 0.60 0.65 0.59
Feb 14, 2024 0.59 -0.02 -3.28% 0.61 0.61 0.58
Feb 13, 2024 0.60 -0.02 -3.23% 0.62 0.62 0.59
Feb 12, 2024 0.65 0.03 4.84% 0.62 0.66 0.62
Feb 9, 2024 0.59 0.04 7.27% 0.55 0.59 0.55
Feb 8, 2024 0.54 -0.01 -1.82% 0.55 0.55 0.53
Feb 7, 2024 0.54 -0.02 -3.57% 0.56 0.56 0.53
Feb 6, 2024 0.59 0.01 1.72% 0.58 0.59 0.56
Feb 5, 2024 0.59 0.00 0.00% 0.59 0.60 0.54
Feb 2, 2024 0.57 0.01 1.79% 0.56 0.58 0.56
Feb 1, 2024 0.58 0.03 5.45% 0.55 0.58 0.54
Jan 31, 2024 0.55 0.05 10.00% 0.50 0.56 0.50
Jan 30, 2024 0.49 -0.05 -9.26% 0.54 0.54 0.49
Jan 29, 2024 0.53 0.01 1.92% 0.52 0.53 0.52
Jan 26, 2024 0.51 0.01 2.00% 0.50 0.51 0.48
Jan 25, 2024 0.49 0.01 2.08% 0.48 0.50 0.48

Viracta Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, March 11, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Viracta Therapeutics Inc Earnings Release
Q4 2023 Viracta Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Viracta Therapeutics Inc Earnings Release
Q1 2024 Viracta Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

17:00

Country

US

Event

Viracta Therapeutics Inc Annual Shareholders Meeting
Viracta Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0.12 2.073 0.237
Revenue 0.12 2.073 0.237
Total Operating Expense 50.589 114.019 22.423 25.361 25.947
Selling/General/Admin. Expenses, Total 24.327 15.437 10.164 9.949 11.332
Research & Development 26.262 23.861 12.259 15.412 14.615
Operating Income -50.589 -114.019 -22.303 -23.288 -25.71
Interest Income (Expense), Net Non-Operating 0.594 -0.453 -0.302 -0.514 -1.154
Other, Net 0.798 -0.29 0.995 0.472 0.249
Net Income Before Taxes -49.197 -114.762 -21.61 -23.33 -26.615
Net Income After Taxes -49.197 -114.762 -21.61 -23.33 -26.615
Net Income Before Extra. Items -49.197 -114.762 -21.61 -23.33 -26.615
Net Income -49.197 -114.762 -21.61 -23.33 -26.615
Income Available to Common Excl. Extra. Items -49.197 -114.762 -21.61 -23.33 -26.615
Income Available to Common Incl. Extra. Items -49.197 -114.762 -21.61 -23.33 -26.615
Dilution Adjustment
Diluted Net Income -49.197 -114.762 -21.61 -23.33 -26.615
Diluted Weighted Average Shares 37.791 31.8701 4.02657 2.48936 1.01661
Diluted EPS Excluding Extraordinary Items -1.30182 -3.60093 -5.36685 -9.37188 -26.1801
Diluted Normalized EPS -1.30182 -0.83279 -5.01916 -9.37188 -26.1801
Total Extraordinary Items
Unusual Expense (Income) 0 88.221
Other Operating Expenses, Total 0 -13.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 12.45 12.207 11.574 18.078 10.505
Selling/General/Admin. Expenses, Total 4.253 4.6 4.871 10.939 4.181
Research & Development 8.197 7.607 6.703 7.139 6.324
Unusual Expense (Income) 0 0 0
Other Operating Expenses, Total 0
Operating Income -12.45 -12.207 -11.574 -18.078 -10.505
Interest Income (Expense), Net Non-Operating -0.034 -0.002 0.45 0.335 -0.077
Other, Net 0.798 0 0
Net Income Before Taxes -12.484 -12.209 -10.326 -17.743 -10.582
Net Income After Taxes -12.484 -12.209 -10.326 -17.743 -10.582
Net Income Before Extra. Items -12.484 -12.209 -10.326 -17.743 -10.582
Net Income -12.484 -12.209 -10.326 -17.743 -10.582
Income Available to Common Excl. Extra. Items -12.484 -12.209 -10.326 -17.743 -10.582
Income Available to Common Incl. Extra. Items -12.484 -12.209 -10.326 -17.743 -10.582
Diluted Net Income -12.484 -12.209 -10.326 -17.743 -10.582
Diluted Weighted Average Shares 38.5604 38.4588 38.3214 37.7055 37.5992
Diluted EPS Excluding Extraordinary Items -0.32375 -0.31746 -0.26946 -0.47057 -0.28144
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.32375 -0.31746 -0.26946 -0.47057 -0.28144
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 93.747 105.273 22.144 36.322 15.2
Cash and Short Term Investments 91.043 103.554 20.41 29.125 13.696
Cash & Equivalents 36.773 103.554 20.41 12.761 13.696
Short Term Investments 54.27 16.364 0
Prepaid Expenses 2.704 1.719 1.734 1.697 1.504
Total Assets 95.991 108.552 23.247 37.24 15.324
Property/Plant/Equipment, Total - Net 0.414 0.882 0.273 0.82 0.011
Total Current Liabilities 10.011 9.084 3.31 9.416 11.323
Accounts Payable 2.54 2.901 0.479 0.791 1.393
Accrued Expenses 7.471 6.183 2.831 3.16 2.534
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 5.465 7.396
Other Current Liabilities, Total
Total Liabilities 34.888 14.181 3.31 9.697 11.331
Total Long Term Debt 24.877 4.819 0 0 0
Long Term Debt 24.877 4.819
Other Liabilities, Total 0 0.278 0 0.281 0.008
Total Equity 61.103 94.371 19.937 27.543 3.993
Preferred Stock - Non Redeemable, Net 5.452 5.452 5.545 11.769 20.998
Common Stock 0.004 0.004 0.002 0.011 0.004
Additional Paid-In Capital 270.699 254.592 718.8 698.562 642.46
Retained Earnings (Accumulated Deficit) -214.874 -165.677 -704.41 -682.8 -659.469
Other Equity, Total -0.178 0 0.001 0
Total Liabilities & Shareholders’ Equity 95.991 108.552 23.247 37.24 15.324
Total Common Shares Outstanding 38.3451 37.4249 5.17364 3.18266 1.07069
Other Long Term Assets, Total 1.83 2.397 0.83 0.098 0.113
Other Current Assets, Total 5.5
Total Preferred Shares Outstanding 0.01025 0.01025
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 64.442 74.555 83.415 93.747 79.68
Cash and Short Term Investments 62.952 72.867 80.332 91.043 77.067
Cash & Equivalents 12.856 14.293 18.099 36.773 23.472
Prepaid Expenses 1.034 1.134 1.791 2.704 2.613
Total Assets 66.437 76.859 85.781 95.991 82.198
Property/Plant/Equipment, Total - Net 0.589 0.757 0.677 0.414 0.546
Other Long Term Assets, Total 1.406 1.547 1.689 1.83 1.972
Total Current Liabilities 36.429 15.213 11.655 10.011 9.387
Accounts Payable 2.363 3.234 2.08 2.54 1.616
Accrued Expenses 8.887 7.693 7.432 7.471 7.771
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 25.179 4.286 2.143
Total Liabilities 36.429 36.077 34.668 34.888 14.386
Total Long Term Debt 0 20.791 22.834 24.877 4.869
Long Term Debt 0 20.791 22.834 24.877 4.869
Other Liabilities, Total 0.073 0.179 0 0.13
Total Equity 30.008 40.782 51.113 61.103 67.812
Preferred Stock - Non Redeemable, Net 5.452 5.452 5.452 5.452 5.452
Common Stock 0.004 0.004 0.004 0.004 0.004
Additional Paid-In Capital 276.784 275.008 272.827 270.699 267.103
Retained Earnings (Accumulated Deficit) -252.167 -239.567 -227.083 -214.874 -204.548
Total Liabilities & Shareholders’ Equity 66.437 76.859 85.781 95.991 82.198
Total Common Shares Outstanding 38.6245 38.5803 38.4109 38.3451 37.9029
Total Preferred Shares Outstanding 0.01025 0.01025 0.01025 0.01025 0.01025
Short Term Investments 50.096 58.574 62.233 54.27 53.595
Other Equity, Total -0.065 -0.115 -0.087 -0.178 -0.199
Total Receivables, Net 0.295 0.312 0.922
Other Current Assets, Total 0.161 0.242 0.37
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -49.197 -114.762 -21.61 -23.33 -26.615
Cash From Operating Activities -35.457 -18.851 -21.439 -22.185 -24.404
Cash From Operating Activities 0.21 0.178 0.009
Non-Cash Items 12.922 94.053 0.488 1.795 2.829
Cash Interest Paid 0.454 0.343 0.339 0.695 0.79
Changes in Working Capital 0.608 1.68 -0.317 -0.65 -0.627
Cash From Investing Activities -53.866 12.891 16.407 -16.285 4.78
Capital Expenditures -0.045 -0.252 0
Other Investing Cash Flow Items, Total -53.821 13.143 16.407 -16.285 4.78
Cash From Financing Activities 22.542 62.425 7.181 43.035 6.343
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net 2.556 62.659 12.681 45.082 6.343
Issuance (Retirement) of Debt, Net 19.986 -0.234 -5.5 -2.047 0
Net Change in Cash -66.781 56.465 2.149 4.565 -13.281
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -12.209 -49.197 -38.871 -21.128 -10.546
Cash From Operating Activities -11.34 -35.457 -27.554 -20.397 -11.363
Cash From Operating Activities 0.122 0.21 0.153 0.108 0.054
Non-Cash Items 1.589 12.922 11.199 3.728 1.772
Cash Interest Paid 0.579 0.454 0.332 0.208 0.102
Changes in Working Capital -0.842 0.608 -0.035 -3.105 -2.643
Cash From Investing Activities -7.35 -53.866 -53.663 -1.606 0
Other Investing Cash Flow Items, Total -7.35 -53.821 -53.618 -1.562 0
Cash From Financing Activities 0.016 22.542 1.135 0.032 0.008
Issuance (Retirement) of Stock, Net 0.016 2.556 1.135 0.032 0.008
Net Change in Cash -18.674 -66.781 -80.082 -21.971 -11.355
Capital Expenditures -0.045 -0.045 -0.044
Issuance (Retirement) of Debt, Net 19.986
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
aMoon Fund Venture Capital 19.1606 7392237 0 2023-04-19 LOW
BVF Partners L.P. Hedge Fund 9.3692 3614662 0 2023-06-30 LOW
Forward Ventures Services, LLC Venture Capital 6.9071 2664790 0 2023-04-19 LOW
Citadel Advisors LLC Hedge Fund 3.9407 1520343 -36980 2023-06-30 LOW
Medical Strategy GmbH Investment Advisor 2.9912 1154012 0 2023-05-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9754 1147912 0 2023-06-30 LOW
Royston (Ivor) Individual Investor 1.898 732245 25219 2023-08-25 LOW
Laurion Capital Management LP Hedge Fund 1.8092 698000 0 2023-06-30 HIGH
Samsara BioCapital, LLC Venture Capital 1.7877 689709 0 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.1765 453879 11027 2023-06-30 LOW
MAI Capital Management, LLC Investment Advisor/Hedge Fund 0.7972 307570 -71898 2023-06-30 LOW
Aisling Capital Management LP Investment Advisor/Hedge Fund 0.748 288571 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5817 224438 0 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.435 167818 71683 2023-06-30 MED
Renaissance Technologies LLC Hedge Fund 0.3494 134799 9500 2023-06-30 HIGH
Bridgeway Capital Management, LLC Investment Advisor 0.324 125000 0 2023-06-30 MED
Chevallard (Daniel R) Individual Investor 0.2479 95653 3376 2023-08-28 LOW
Pomerantz (Roger J) Individual Investor 0.2107 81307 9034 2023-08-25 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.1707 65867 0 2023-06-30 LOW
Ensign Peak Advisors, Inc. Foundation 0.1643 63406 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Viracta Therapeutics, Inc. Company profile

About Viracta Therapeutics Inc

Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Viracta Therapeutics Inc revenues decreased from $120K to $0K. Net loss increased from $21.6M to $114.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 85% to $21.7M (expense), Stock-based Compensation in SGA increase from $530K to $3.4M (expense).

Equity composition

Common Stock $.0001 Par, $400M. auth., 04/11, 46,027,474 issd. Insiders own 6.84%. IPO: 9/05, 6M shs. @ $7 by LehmanBrothers. 02/11, 1-for-6 reverse stock split. Preferred Stock $.0001 Par, $10M. auth., 12/10, 0 issd.

Industry: Biotechnology & Medical Research (NEC)

2533 S Coast Hwy 101
Suite 210
CARDIFF BY THE SEA
CALIFORNIA 92007
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

BTC/USD

51,208.95 Price
-0.920% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

77.60 Price
-0.790% 1D Chg, %
Long position overnight fee 0.0162%
Short position overnight fee -0.0381%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.54 Price
-1.930% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,022.85 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading